Zelira Therapeutics Ltd (ASX: ZLD) is a cannabis group that works on a varied range of formulations based on cannabinoid for treating several medical conditions. The group has partnerships with well-known names such as Aunt Zelda’s, CannPal, and Curtin University to name a few. The Company is working on 2 approaches that involve a human clinical trial program for conditions such as insomnia, autism and eczema; and a pre-clinical research program for impact of cannabinoids in breast, brain and pancreatic cancer. The new approach being worked upon includes potential for cannabinoids to treat diabetes-associated cognitive decline. The group operates in Australia, the United States and Chile.